Frank M. Schabel 1918-1983

H E Skipper, D P Griswold

Cancer Research

|February 1, 1984

Summary

No abstract available in PubMed .

Related Concept Videos

You might also read

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Journal of the American Academy of Nurse Practitioners·2002

Same author

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Journal of the National Cancer Institute·1992

Same author

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Cancer chemotherapy and pharmacology·1992

Same author

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Cancer chemotherapy and pharmacology·1992

Same author

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Cancer chemotherapy and pharmacology·1992

Same author

Tumor models in drug development.

Cancer metastasis reviews·1991

Same journal

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

Cancer research·2026

Same journal

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

Cancer research·2026

Same journal

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

Cancer research·2026

Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026

Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026

Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026

See all related articles

Related Experiment Videos

Frank M. Schabel 1918-1983

Related Concept Videos

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Tumor models in drug development.

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Related Experiment Videos

Frank M. Schabel 1918-1983

Related Concept Videos

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Tumor models in drug development.

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Related Experiment Videos

Frank M. Schabel 1918-1983

Related Concept Videos

Related Articles

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Tumor models in drug development.

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Related Experiment Videos

Frank M. Schabel 1918-1983

Related Concept Videos

Related Articles

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.

Tumor models in drug development.

Targeting Cystine Addiction Suppresses Breast Cancer Lung Metastasis.

SEPTIN7 Enhances Tumorgenesis and Therapeutic Resistance in Hepatocellular Carcinoma by Promoting FGFR4 Stabilization and Recycling.

TLR9 Agonists Potentiate Adoptive T Cell Therapy in Cancer through a B Cell-CD2 Costimulatory Axis.

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.